Bellevue Group AG Has $35.10 Million Stake in Eli Lilly and Company (NYSE:LLY)

Bellevue Group AG boosted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 2.8% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 45,465 shares of the company's stock after acquiring an additional 1,219 shares during the period. Bellevue Group AG's holdings in Eli Lilly and Company were worth $35,099,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. grew its position in Eli Lilly and Company by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 74,248,997 shares of the company's stock worth $57,320,226,000 after acquiring an additional 475,530 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Eli Lilly and Company by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 17,382,846 shares of the company's stock valued at $13,389,651,000 after buying an additional 291,875 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Eli Lilly and Company by 19.0% during the 4th quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock worth $9,747,214,000 after acquiring an additional 2,012,129 shares during the last quarter. Norges Bank purchased a new position in Eli Lilly and Company during the 4th quarter valued at $8,407,908,000. Finally, Capital Research Global Investors grew its holdings in shares of Eli Lilly and Company by 16.1% in the fourth quarter. Capital Research Global Investors now owns 10,757,511 shares of the company's stock worth $8,304,811,000 after purchasing an additional 1,493,673 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.14% of the stock is owned by company insiders.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY traded up $1.82 during midday trading on Wednesday, hitting $776.94. The company's stock had a trading volume of 3,727,176 shares, compared to its average volume of 3,486,594. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The firm's fifty day moving average price is $820.91 and its 200-day moving average price is $814.03. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The firm has a market cap of $736.33 billion, a P/E ratio of 66.35, a P/E/G ratio of 1.40 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The company had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. During the same quarter in the previous year, the business posted $2.58 earnings per share. The business's quarterly revenue was up 45.2% compared to the same quarter last year. On average, sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be paid a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.77%. The ex-dividend date is Friday, May 16th. Eli Lilly and Company's dividend payout ratio is presently 48.82%.

Analyst Ratings Changes

LLY has been the subject of a number of research analyst reports. HSBC lowered Eli Lilly and Company from a "buy" rating to a "reduce" rating and decreased their target price for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. StockNews.com raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Friday, February 7th. Hsbc Global Res downgraded Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and lowered their price target for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. Finally, Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nineteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $1,002.80.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.